Market Views – Page 20 – media

Sanofi snaps up Ablynx for 3.9bn euros

Sanofi will launch public offers to acquire all shares, including ADSs, warrants and convertible bonds of Ablynx. News of the deal will no doubt come as a great disappointment to Novo Nordisk, which recently stepped up its efforts to buy Ablynx with a second offer valued at around 2.6 billion euros.
- Source: Currenthollywood
- 642
- January 30, 2018
Market Views Sanofi Ablynx
Cybersecurity for Medical Device Endpoints

With the recent, highly publicized incidents of identity theft, ransomware and malware attacks directed at healthcare facilities, the medical device community is on high-security alert.
- Source: WIBU Systems
- 791
- January 29, 2018
cybersecurity FDA Market Views medical device
Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.

Spark Therapeutics (ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the U.S.
- Source: finance.yahoo
- 532
- January 26, 2018
Gene therapy Market Views voretigene neparvovec
China’s digital healthcare transformation – private hospital achieve HIMSS milestone

Explosive growth and groundbreaking digital transformations are underway in China’s enormous healthcare market, and now a Beijing hospital has become the first private healthcare organisation in the nation to achieve Stage 6 on the HIMSS EMRAM scale for its electronic medical record system.
- Source: Healthcare IT
- 529
- January 25, 2018
China health IT healthcare Market Views
Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offer

Celgene agreed on Monday to buy the rest of Juno Therapeutics it doesn't already own for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.
- Source: Cnbc
- 981
- January 24, 2018
cancer CAR–T Market Views
Sanofi to acquire Bioverativ for $11.6 billion

Sanofi SA (SAN.FR) said Monday that it will acquire all outstanding shares in Bioverativ Inc. BIVV, -0.61% for $11.6 billion to expand its presence in specialty care and strengthening leadership in rare diseases.
- Source: Marketwatch
- 480
- January 24, 2018
Market Views rare diseases
Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars

Sandoz, a Novartis division and the global leader in biosimilars, announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.
- Source: Sandoz
- 594
- January 23, 2018
biosimilars immunology Market Views oncology
Merck KGaA taps UK cancer research organizations to feed pipeline

After an R&D drought that lasted more than a decade, Merck KGaA may be coming out of the desert. Following two recent drug approvals, including the landmark FDA OK for checkpoint inhibitor Bavencio, the German Merck is now entering an R&D collaboration that might help fill its pipeline with new cancer drug contenders.
- Source: Endpts
- 561
- January 23, 2018
Bavencio cancer inhibitor Market Views
IoT devices vulnerable to Spectre and Meltdown exploitation

Healthcare organizations should use risk management processes to ensure the security of health information and protect against the vulnerabilities stemming from the Spectre and Meltdown threats.
- Source: Healthcare IT News
- 520
- January 23, 2018
healthcare technology Internet of Things Market Views medical device
Adlai Nortye Enters into Global Licensing Agreement with Eisai for EP4 Antagonist

Adlai Nortye Biopharma Co., Ltd. (NEEQ: 870946) ("Adlai Nortye" or "the Company"), a biopharmaceutical company dedicated to discovery and commercialization of new and effective drugs, announced today that it had entered into a Global Licensing Agreement ("the Agreement") with Eisai Co., Ltd. ("Eisai"), a global pharmaceutical company with a focus on serving patients with unmet medical needs.
- Source: Prnewswire
- 768
- January 22, 2018
biopharmaceutical EP4 antagonist Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.